Non-Alcoholic Steatohepatitis (NASH)
Treatment Market
Non-Alcoholic Steatohepatitis (NASH) Treatment
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Non-Alcoholic Steatohepatitis (NASH) Treatment
Market Size and Growth
The Non-Alcoholic Steatohepatitis (NASH) treatment market is expanding rapidly, driven by increasing prevalence and demand for effective therapies. The global market size is projected to reach approximately $10 billion by 2028, influenced by ongoing clinical trials and emerging treatments aimed at improving patient outcomes and addressing associated liver disease complications.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Allergan Plc (Tobira)
◍ Bristol Myers Squibb
◍ Galmed Pharmaceuticals
◍ Genfit SA
◍ Gilead Sciences, Inc.
◍ Intercept Pharmaceuticals, Inc.
◍ Zydus Cadila
The NASH treatment market is competitive, with key players like Allergan, Bristol Myers Squibb, Galmed, Genfit, Gilead, Intercept, and Zydus Cadila developing innovative therapies. These companies contribute to market growth through research, strategic collaborations, and expanding clinical trials. Revenue figures include Gilead's $4.7 billion and Bristol’s $3 billion.
Request Sample Report
Market Segmentation
By Application
Hospital Pharmacy
Online Provider
Retail Pharmacy
Request Sample Report
By Product
Off-Label
Therapeutic
Market Growth
Request Sample Report
$ X Billion USD
